INNOVENT BIO (01801): Seven innovative products, including Dabaso and Ximilin, have been successfully included in the 2025 edition of the National Medical Insurance Drug List, including new indications.

INNOVENT BIO (01801) announced that seven innovative products have been successfully included in the new National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug List (2025), including: Tyvyt (Sintilimab Injection, anti-PD-1 monoclonal antibody) with new indications, IBI301 (Tyruvatinib N01 Injection, anti-IGF-1R monoclonal antibody), Ou Yi Xin (Elretinib Tablets, EGFR TKI), Vizimpro (Fluorozole Tablets, KRAS G12C inhibitor), Davatch (Hextanthetanib Capsules, ROS1TKI), Suzutinib (Seterinib Capsules, RET inhibitor), and Jupally (Ibrutinib Tablets, BTK inhibitor). The new National Medical Insurance Drug List will officially be implemented starting from January 1, 2026. This time, the company's seven innovative drugs have been successfully included in the National Medical Insurance Drug List, covering tumor (lung cancer, liver cancer, gastric cancer, esophageal cancer, gynecological tumors, and hematological tumors) as well as cardiovascular and metabolic diseases with heavy social burden. This will continue to improve the accessibility and affordability of medication for patients, benefiting more LBX Pharmacy Chain Joint Stock in China. The company adheres to the corporate mission of "developing high-quality biopharmaceuticals that LBX Pharmacy Chain Joint Stock can afford," continues to innovate, and forge ahead. The company will continue to prioritize patients, actively cooperate with medical insurance policies in various regions, and ensure that high-quality drugs can benefit more patients and families as soon as possible.